ACTU (Actuate Therapeutics Inc) Yalpi marja

Actuate Therapeutics Inc (ACTU) korporativ emblemasi va logotipi

GSK-3B inhibitorlarini ishlab chiqishga yo'naltirilgan yuqori R&D xarajatlari Actuate Therapeutics, Inc. (ACTU) moliyaviy profilini belgilaydi. GURU.Markets platformasidagi yalpi foyda marjasi dinamikasi ushbu muvozanatni aks ettiradi va joriy ko'rsatkich 0.00 darajasida turibdi. Solid o'smalar terapiyasini ishlab chiqish kompaniyaning bozordagi mavjudligini kengaytiradi, onkologik dori vositalari uchun optimallashtirilgan aniq sovuq zanjir logistikasi esa yuqori operatsion samaradorlikni va yuqori qiymatli yuklar yaxlitligini ta'minlaydi.

Actuate Therapeutics, Inc (ACTU) - Yalpi marja 14.08.2024dan 20.11.2026gacha

Actuate Therapeutics, Inc (ACTU) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Fundamental baholash:Actuate Therapeutics (ACTU)
Actuate Therapeutics Inc. tomonidan chiqariladigan mahsulotlar

Raqobatchilar tomonidan bevosita narxlar bosimi bo'lmagan holda saraton terapiyasi uchun noyob ingibitorlarning ishlab chiqilishi Actuate Therapeutics, Inc. (ACTU) kompaniyasiga o'z mahsulotlari uchun yuqori qo'shilgan qiymat yaratish imkonini beradi. Valo martba (gross margin) tuzilmasini tahlil qilish orqali investor ishlab chiqarish xarajatlaridan keyin qolgan daromad qismini baholaydi, bunda o'sish tendentsiyasi biznes modelining samaradorligini tasdiqlasa, keskin pasayish sotilgan tovarlar xarajatlarining ortishi yoki operatsion risklar haqida signal beradi.

Toʻgʻridan-toʻgʻri raqobatchilar

Yalpi foyda marjasi BeiGene Ltd. (ONC)|Yalpi foyda bo'yicha rentabellik HALO|Yalpi rentabellik RVMD|Yalpi foyda bo'yicha rentabellik AAPG (Ascentage)|Yalpi foyda bo'yicha rentabellik cgoncology.com CGON|UroGen Pharma - Yalpi foyda bo'yicha rentabellik|Yalpi foyda normasi BCAX|PSNL - Yalpi rentabellik|Yalpi foyda bo'yicha sotuv rentabelligi Erasca Oncology ERAS|delcath.com (DCTH) - Yalpi rentabellik|Y-mAbs Therapeutics - Yalpi foyda normasi|AURA (Aura Biosciences Inc) - Yalpi marja|Yalpi foyda marjasi candeltx.com CADL|Yalpi marja ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Yalpi foyda normasi|Yalpi rentabellik Citius Oncology, Inc. CTOR|HURA - Yalpi foyda bo'yicha rentabellik|protaratx.com - Yalpi marja|FATE - Yalpi marja|WHWK: Yalpi marja|TScan Therapeutics (TCRX) - Yalpi marja|Yalpi rentabellik Champions Oncology|Yalpi rentabellik XBIT|Yalpi marja CVM|Yalpi foyda bo'yicha rentabellik OS Therapies Inc. OSTX|Yalpi rentabellik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Yalpi foyda marjasi|ANL - Yalpi rentabellik|Yalpi foyda marjasi verupharma.com|TPST: Yalpi marja|XLO - Yalpi foyda bo'yicha sotuv rentabelligi|Yalpi rentabellik Renovaro|Yalpi marja muraloncology.com|Yalpi marja KAPA|Yalpi foyda bo'yicha sotuv rentabelligi OnKure Therapeutics, Inc.|Yalpi marja GDTC (w2.cytomed.sg)|CRIS - Yalpi foyda bo'yicha rentabellik|Apollomics - Yalpi marja|Tharimmune Corp (THAR) - Yalpi foyda bo'yicha rentabellik|ADVB: Yalpi marja|Yalpi foyda bo'yicha rentabellik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Yalpi marja|Sotuvning yalpi rentabelligi SBFM (Sunshine Biopharma)|Yalpi rentabellik Xenetic Bio (XBIO)|Yalpi rentabellik SLRX (Salarius Pharma)|Kitov Pharma - Yalpi foyda bo'yicha rentabellik|American Oncology Network (AONC) - Yalpi foyda marjasi|BeiGene - Yalpi marja|Checkpoint Therapeutics, Inc. (CKPT) - Yalpi foyda bo'yicha rentabellik|ELEV (Elevation Oncology, Inc.) - Yalpi foyda bo'yicha rentabellik|iCAD Inc. - Yalpi foyda normasi|Yalpi foyda bo'yicha rentabellik IKNA|Yalpi marja notablelabs.com|Yalpi foyda bo'yicha rentabellik VIRX (Viracta Therapeutics Inc.)|MOR - Yalpi foyda marjasi|Yalpi rentabellik NAYA Biosciences NAYA|AAPGV - Yalpi foyda bo'yicha rentabellik